These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3082003)

  • 1. [Treatment of multiple myeloma].
    Clément F
    Schweiz Med Wochenschr; 1986 Feb; 116(8):230-9. PubMed ID: 3082003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and therapeutic results in multiple myeloma.
    Nagai M; Kitahara T; Minato K; Takenaka T; Konda C; Seki S; Shimoyama M
    Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiated treatment of myeloma. A non-randomised phase two study.
    Osby E; Reizenstein P
    Anticancer Res; 1984; 4(3):163-4. PubMed ID: 6465855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tumor-forming type of multiple myeloma. II. Clinical profile and therapeutic effect.
    Sezaki T; Hujita M; Oka A; Tanaka T
    Acta Med Okayama; 1979 Dec; 33(6):451-4. PubMed ID: 161470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hemocytological classification, clinical staging and polychemotherapy of multiple myeloma].
    István L; Karl W; Michael H; Günter A; Kelényi G; Várbíró M; Dieter R
    Orv Hetil; 1983 Feb; 124(6):313-9. PubMed ID: 6835675
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of paraproteinemic hemoblastoses].
    Fereberger W
    Acta Med Austriaca; 1982; 9(4):151-7. PubMed ID: 6814158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasmocytic pleural effusion disclosing multiple myeloma].
    Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
    Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio.
    Riccardi A; Montecucco C; Danova M; Ucci G; Merlini G; Ascari E
    Cancer Treat Rep; 1985 Sep; 69(9):971-5. PubMed ID: 4028038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
    Sakalová A; Holománová D; Mikulecký M; Mistrík M; Lipsic T; Steruská M
    Neoplasma; 1993; 40(6):351-4. PubMed ID: 8289966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
    Lin P; Owens R; Tricot G; Wilson CS
    Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring.
    Kühnemund A; Liebisch P; Bauchmüller K; zur Hausen A; Veelken H; Wäsch R; Engelhardt M
    J Cancer Res Clin Oncol; 2009 Mar; 135(3):477-84. PubMed ID: 18802723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunoglobulin subclasses and multiple myeloma. Clinico-biological correlations, with special reference to IgG3 myelomas (author's transl)].
    San Miguel J; Hernández F; Vicente V; Recio M; López Borrasca A
    Sangre (Barc); 1980; 25(6):1034-9. PubMed ID: 7221825
    [No Abstract]   [Full Text] [Related]  

  • 17. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interferon therapy in multiple myeloma].
    Micksche M
    Wien Med Wochenschr; 1993; 143(16-17):425-8. PubMed ID: 8273366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.